Washington, D.C. 20549



Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): June 22, 2020


(Exact name of registrant as specified in its charter)


Delaware   000-05576   52-0849320

(State or other jurisdiction

of incorporation) 



File Number) 


(I.R.S. Employer

Identification No.) 


One Rockefeller Plaza, 11th Floor, New York, NY   10020
(Address of principal executive offices)   (Zip Code)
Registrant’s telephone number, including area code: (703) 992-9325


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ☐


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   AIKI   The Nasdaq Capital Market




Item 8.01.   Other Events.


On June 22, 2020, certain owners (the “Sellers”) of 1,512,465 shares of common stock, par value $0.001 (the “Shares”), of AIkido Pharma Inc., a Delaware corporation (the “Company”), sold the Shares to a healthcare-dedicated investment fund (the “Fund”), pursuant to that certain Stock Purchase Agreement, by and among the Fund and the Sellers (the “Sale”). The Shares sold in the Sale were subject to restrictions (the “Restrictions”) pursuant to that certain Leak-Out Agreement, dated as of December 5, 2019, by and between the Company and CBM BioPharma, Inc., a Delaware corporation. The Restrictions were lifted pursuant to that certain Termination Agreement, dated as of June 24, 2020, by and between the Company and the Fund.






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By:  /s/ Anthony Hayes



Anthony Hayes
Chief Executive Officer

Dated: June 25, 2020